Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns show up across Guardant Health's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.
2 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
Guardant purchased all of the remaining shares of Guardant Health AMEA, Inc. held by SoftBank (SVF Excalibur (Cayman) Limited) and its affiliates, giving Guardant full control over its liquid-biopsy operations across the Asia, Middle East and Africa region. The AMEA entity, established in May 2018 as a joint venture between Guardant Health and the SoftBank Vision Fund, serves 41 countries across the region. The purchase price of $177.8 million was determined based on an independent third-party valuation, and the joint venture agreement was terminated concurrently with the closing. approximately $177.8 million.
By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer and improve patient outcomes. We believe our blood-based tests can play a significant role in helping address the growing cancer burden in the region, and we look forward to continuing to support patients facing cancer diagnoses as we expand our operations in these markets.Helmy Eltoukhy — Chairman and co-CEO, Guardant Health
In December 2025 Guardant Health purchased all of the outstanding shares of MetaSight Diagnostics Ltd., a health technology company. The transaction included $59.0 million in upfront cash consideration paid at closing, plus up to $90.0 million in variable contingent consideration tied to future commercial performance and regulatory approvals of the MetaSight technology. Total purchase consideration net of cash acquired was $93.0 million, with the contingent consideration carried at a fair value of $34.0 million as of the acquisition date. The excess of purchase consideration over the fair value of net assets acquired was recorded as goodwill, attributable to future revenue opportunities Guardant expects from leveraging the acquired technologies. $93.0 million total purchase consideration net of cash ($59.0 million upfront cash plus up to $90.0 million contingent; $34.0 million contingent fair value at acquisition date).
In December 2025, the Company purchased all of the outstanding shares of MetaSight Diagnostics Ltd., or MetaSight, a health technology company. The transaction includes $59.0 million in upfront cash consideration paid at closing, plus up to $90.0 million in variable contingent consideration tied to future commercial performance and regulatory approvals of the MetaSight technology.Guardant Health FY25 10-K — Note 4 Acquisition